| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1600-0447.2008.01204.X |
| P698 | PubMed publication ID | 18498432 |
| P50 | author | Adriane R Rosa | Q57623776 |
| Carla Torrent | Q73270026 | ||
| Eduard Vieta | Q20090640 | ||
| Jose Sanchez-Moreno | Q47810763 | ||
| Benedikt L Amann | Q42368543 | ||
| Jan Scott | Q45741573 | ||
| Francesc Colom | Q45741583 | ||
| P2093 | author name string | M Reinares | |
| M Comes | |||
| P2860 | cites work | A Randomized Trial on the Efficacy of Group Psychoeducation in the Prophylaxis of Recurrences in Bipolar Patients Whose Disease Is in Remission | Q57612892 |
| Weight gain and serum leptin levels in patients on lithium treatment | Q47176359 | ||
| Antidepressants and weight gain | Q47182761 | ||
| Chronic imipramine treatment and weight gain | Q47210718 | ||
| Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. | Q47233080 | ||
| Weight gain. A side-effect of tricyclic antidepressants | Q47235261 | ||
| Weight gain in depression remitted with antidepressants: pharmacological or recovery effect? | Q47283733 | ||
| Changes in body weight with chronic, high-dose gabapentin therapy | Q47304187 | ||
| Weight gain occurs after onset of bipolar illness in overweight bipolar patients | Q47310353 | ||
| Differential effect of clozapine on weight: a controlled study | Q47331289 | ||
| Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study | Q47777106 | ||
| Health-related quality of life in patients with class II and class III obesity | Q48539592 | ||
| Case for caution, case for action. | Q51013896 | ||
| Introduction to special issue on antidepressant use in bipolar disorder. | Q51013911 | ||
| Obesity and endocrine disorders in women taking valproate for epilepsy. | Q51034614 | ||
| Non-adherence in psychiatric disorders: misbehaviour or clinical feature? | Q51958126 | ||
| Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group. | Q53956450 | ||
| Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder | Q56138336 | ||
| Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults | Q22250906 | ||
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial | Q28208895 | ||
| Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial | Q28259736 | ||
| Effects of Nefazodone on Body Weight | Q29038379 | ||
| A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder | Q29394100 | ||
| Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation | Q29547453 | ||
| The metabolic syndrome--a new worldwide definition | Q29615125 | ||
| Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion | Q33638831 | ||
| Body weight gain induced by antipsychotic drugs: mechanisms and management | Q33708467 | ||
| Short-term and long-term treatment for bipolar patients: beyond the guidelines | Q33747481 | ||
| The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke | Q33891455 | ||
| A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders | Q33927263 | ||
| Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression | Q34275783 | ||
| Bodyweight gain and anticonvulsants: a comparative review | Q34458567 | ||
| A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression | Q34492390 | ||
| Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group | Q34514128 | ||
| Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review | Q35014566 | ||
| Valproate | Q35142736 | ||
| Antidepressants in bipolar disorder: the case for caution | Q35592492 | ||
| Psychological interventions in bipolar disorder: From wishful thinking to an evidence-based approach | Q35872071 | ||
| The Metabolic Syndrome in Patients With Severe Mental Illnesses | Q35884715 | ||
| Treatment guidelines for bipolar disorder: a critical review. | Q36093544 | ||
| Hypothalamic-pituitary-adrenal axis and bipolar disorder. | Q36096503 | ||
| Valproate in bipolar disorder: 2000 onwards | Q36099536 | ||
| Mood stabilization in the treatment of bipolar disorder: focus on quetiapine | Q36119897 | ||
| Atypical antipsychotics: newer options for mania and maintenance therapy | Q36158824 | ||
| Identifying and improving non-adherence in bipolar disorders. | Q36286408 | ||
| Practical considerations for carbamazepine use in bipolar disorder | Q36506812 | ||
| Evolving trends in the long-term treatment of bipolar disorder | Q36762209 | ||
| Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder | Q37152810 | ||
| Depression, antidepressants, and body weight change | Q38780289 | ||
| Maintenance therapy for bipolar disorder: current and future management options | Q40373746 | ||
| Drugs that cause weight gain | Q41026135 | ||
| Bodyweight change as an adverse effect of drug treatment. Mechanisms and management | Q41107969 | ||
| Algorithms for bipolar mania | Q41621574 | ||
| Prospective studies on a lithium cohort. 3. Tremor, weight gain, diarrhea, psychological complaints | Q42211229 | ||
| A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group | Q42626284 | ||
| Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group | Q43507067 | ||
| Prevalence of obesity and weight change during treatment in patients with bipolar I disorder | Q43642752 | ||
| A program for treating olanzapine-related weight gain | Q43658674 | ||
| Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy | Q43846648 | ||
| Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania | Q43942949 | ||
| Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks | Q43997800 | ||
| Olanzapine versus divalproex in the treatment of acute mania | Q44013092 | ||
| Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism | Q44043068 | ||
| Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety | Q44045819 | ||
| A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania | Q44168457 | ||
| Spotlight on lamotrigine in bipolar disorder | Q44200740 | ||
| Gabapentin augmentation therapy in bipolar depression | Q44247103 | ||
| Obesity as a correlate of outcome in patients with bipolar I disorder | Q44265285 | ||
| Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial | Q44299951 | ||
| Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial | Q44385585 | ||
| A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder | Q44403599 | ||
| Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials | Q44428863 | ||
| Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol | Q44470652 | ||
| Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study | Q44495168 | ||
| Antipsychotic-induced weight gain: bipolar disorder and leptin | Q44550771 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania | Q44684784 | ||
| Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone | Q44824135 | ||
| Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. | Q44962387 | ||
| Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol | Q45168624 | ||
| Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study | Q45209951 | ||
| Metabolic syndrome: definition, pathophysiology, and mechanisms | Q45230910 | ||
| A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group | Q45336272 | ||
| A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder | Q46503060 | ||
| Risperidone in the treatment of acute mania: double-blind, placebo-controlled study | Q46681460 | ||
| Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial | Q46681464 | ||
| Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice | Q46687256 | ||
| Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians | Q46714706 | ||
| Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children | Q46765699 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| bipolar disorder | Q131755 | ||
| weight gain | Q3403879 | ||
| P304 | page(s) | 4-18 | |
| P577 | publication date | 2008-05-22 | |
| P1433 | published in | Acta Psychiatrica Scandinavica | Q4033348 |
| P1476 | title | Weight gain in bipolar disorder: pharmacological treatment as a contributing factor | |
| P478 | volume | 118 |
| Q35833294 | A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder |
| Q36929364 | A psychoeducational intervention (SWEEP) for depressed women with diabetes |
| Q34614432 | Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. |
| Q38779572 | Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis |
| Q38285318 | Antiepileptic drugs influences on body weight in people with epilepsy. |
| Q48793990 | Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial |
| Q49494206 | Asenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study. |
| Q47913705 | Body mass index associates with white matter microstructure in bipolar depression. |
| Q36966140 | Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs |
| Q51063946 | Eating behavior and obesity in bipolar disorder. |
| Q36197756 | Effect of Early Intervention with Omega-3 on Insulin Resistance in Patients Initiated on Olanzapine with either Sodium Valproate or Lithium: A randomized, Double-blind, Placebo-Controlled Trial |
| Q34516264 | Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial. |
| Q34676317 | Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology |
| Q40549171 | Gender differences in mood stabilizer medications prescribed to Veterans with serious mental illness |
| Q37365437 | Genetic risk factors for type 2 diabetes with pharmacologic intervention in African-American patients with schizophrenia or schizoaffective disorder |
| Q98466819 | Hidradenitis suppurativa and psychiatric comorbidities, suicides and substance abuse: systematic review and meta-analysis |
| Q33721019 | Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders |
| Q39049252 | Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder? |
| Q37674020 | Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder |
| Q37402610 | Lithium: a key to the genetics of bipolar disorder |
| Q47249575 | Lower cognitive functioning as a predictor of weight gain in bipolar disorder: a 12-month study. |
| Q37623789 | Managing weight in persons living with severe mental illness in community settings: a review of strategies used in community interventions |
| Q33836586 | Metabolic syndrome among psychiatric outpatients with mood and anxiety disorders |
| Q37954425 | Metabolic syndrome and bipolar disorder: what should psychiatrists know? |
| Q41771822 | Metformin for Lithium-induced Weight Gain: A Case Report |
| Q38204626 | Molecular and cellular regulation of hypothalamic melanocortin neurons controlling food intake and energy metabolism |
| Q30897232 | Neurocognitive functioning in overweight and obese patients with bipolar disorder: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM) |
| Q38035727 | Obesity in bipolar disorder: an overview |
| Q47704381 | Obesity in patients with major depression is related to bipolarity and mixed features: evidence from the BRIDGE-II-Mix study |
| Q37997775 | Olanzapine-induced weight gain in patients with bipolar I disorder: a meta-analysis. |
| Q38364834 | Pharmacotherapy of acute mania: monotherapy or combination therapy with mood stabilizers and antipsychotics? |
| Q34623350 | Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. |
| Q44632992 | Prevalence and clinical impact of eating disorders in bipolar patients |
| Q94544871 | Prevalence of Prediabetes and Diabetes Mellitus Type II in Bipolar Disorder |
| Q38151984 | Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins |
| Q38763807 | Psychiatric and physical comorbidities and their impact on the course of bipolar disorder: A prospective, naturalistic 4-year follow-up study |
| Q37255608 | Risk of myocardial infarction and stroke in bipolar disorder: a systematic review and exploratory meta-analysis. |
| Q37031181 | Sequential behavioral treatment of smoking and weight control in bipolar disorder |
| Q39640688 | Sex Differences in Weight Loss among Veterans with Serious Mental Illness: Observational Study of a National Weight Management Program. |
| Q38049775 | Spanish consensus on physical health of patients with bipolar disorder |
| Q98226384 | The association between leptin and adiponectin, and metabolic syndrome components and serum levels of lipid peroxidation in bipolar disorder patients treated with lithium and valproic acid |
| Q38334922 | Treatment of clozapine-associated weight gain: a systematic review. |
| Q38749110 | Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis |
| Q38093728 | Use of asenapine in clinical practice for the management of bipolar mania |
| Q38151453 | Weight considerations in psychotropic drug prescribing and switching |
| Q37865068 | Weight gain associated with taking psychotropic medication: an integrative review |
| Q35577365 | Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles |
Search more.